Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryosuke Nakano

Showing results (11-20 of 94) with videos related to

Pageof 10
Sort By:
European Journal of Pharmacology|January 28, 2009
Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic miceAtsuo Tahara, Akiko Matsuyama-Yokono, Ryosuke Nakano, et al.
Molecular and Cellular Biology|August 29, 2003
Involvement of nucleocytoplasmic shuttling of yeast Nap1 in mitotic progressionMary Miyaji-Yamaguchi, Kohsuke Kato, Ryosuke Nakano, et al.
Pharmacological Reports : PR|November 12, 2009
Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitorsAtsuo Tahara, Akiko Matsuyama-Yokono, Ryosuke Nakano, et al.
Pharmacology|January 30, 2009
Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic miceAtsuo Tahara, Akiko Matsuyama-Yokono, Ryosuke Nakano, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 3, 2008
Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic miceAkiko Matsuyama-Yokono, Atsuo Tahara, Ryosuke Nakano, et al.
International Journal of Molecular Sciences|December 10, 2021
State-Targeting Stabilization of Adenosine A<sub>2A</sub> Receptor by Fusing a Custom-Made De Novo Designed α-Helical ProteinMasaya Mitsumoto, Kanna Sugaya, Kazuki Kazama, et al.
Biochemical Pharmacology|May 16, 2006
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivoRyosuke Nakano, Eiji Kurosaki, Shigeru Yoshida, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2007
An influenza virus replicon system in yeast identified Tat-SF1 as a stimulatory host factor for viral RNA synthesisTadasuke Naito, Yoshihiko Kiyasu, Kenji Sugiyama, et al.
Japanese Journal of Pharmacology|August 20, 2002
Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker ratsEiji Kurosaki, Kazuhiro Momose, Ryosuke Nakano, et al.
European Journal of Pharmacology|May 14, 2003
Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker ratsEiji Kurosaki, Ryosuke Nakano, Kazuhiro Momose, et al.
Pageof 10

Showing results (11-20 of 94) with videos related to

Sort By:
Pageof 10
European Journal of Pharmacology|January 28, 2009
Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic miceAtsuo Tahara, Akiko Matsuyama-Yokono, Ryosuke Nakano, et al.
Molecular and Cellular Biology|August 29, 2003
Involvement of nucleocytoplasmic shuttling of yeast Nap1 in mitotic progressionMary Miyaji-Yamaguchi, Kohsuke Kato, Ryosuke Nakano, et al.
Pharmacological Reports : PR|November 12, 2009
Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitorsAtsuo Tahara, Akiko Matsuyama-Yokono, Ryosuke Nakano, et al.
Pharmacology|January 30, 2009
Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic miceAtsuo Tahara, Akiko Matsuyama-Yokono, Ryosuke Nakano, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 3, 2008
Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic miceAkiko Matsuyama-Yokono, Atsuo Tahara, Ryosuke Nakano, et al.
International Journal of Molecular Sciences|December 10, 2021
State-Targeting Stabilization of Adenosine A<sub>2A</sub> Receptor by Fusing a Custom-Made De Novo Designed α-Helical ProteinMasaya Mitsumoto, Kanna Sugaya, Kazuki Kazama, et al.
Biochemical Pharmacology|May 16, 2006
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivoRyosuke Nakano, Eiji Kurosaki, Shigeru Yoshida, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2007
An influenza virus replicon system in yeast identified Tat-SF1 as a stimulatory host factor for viral RNA synthesisTadasuke Naito, Yoshihiko Kiyasu, Kenji Sugiyama, et al.
Japanese Journal of Pharmacology|August 20, 2002
Hypoglycemic agent YM440 ameliorates the impaired hepatic glycogenesis after glucose loading by increasing glycogen synthase activity in obese Zucker ratsEiji Kurosaki, Kazuhiro Momose, Ryosuke Nakano, et al.
European Journal of Pharmacology|May 14, 2003
Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker ratsEiji Kurosaki, Ryosuke Nakano, Kazuhiro Momose, et al.
Pageof 10